Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. 2012

Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
Division of Vaccine Research, Beth Israel Deaconess Medical Center, and Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.

The immunogenicity of adenovirus serotype 5 (Ad5) vectors has been shown to be suppressed by neutralizing antibodies (NAbs) directed primarily against the hexon hypervariable regions (HVRs). We previously reported that replacing all seven HVRs with those from the rare serotype virus Ad48 resulted in a chimeric Ad5HVR48(1-7) vector that largely evaded preexisting Ad5 immunity in mice and rhesus monkeys. In this study, we evaluated the extent to which Ad5-specific NAbs are directed against various HVRs. We constructed partial HVR-chimeric Ad5 vectors with only a subset of HVRs exchanged, and we utilized these vectors in both NAb assays and murine immunogenicity studies with and without baseline Ad5 immunity. Our results demonstrate that Ad5-specific NAbs target multiple HVRs, suggesting that replacing all HVRs is required to optimize evasion of anti-Ad5 immunity. These data have important implications for the development of novel vectors for both vaccines and gene therapy.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D000258 Adenovirus Infections, Human Respiratory and conjunctival infections caused by 33 identified serotypes of human adenoviruses. Pharyngo-Conjunctival Fever,Human Adenovirus Infections,Infections, Human Adenovirus,Adenovirus Infection, Human,Fever, Pharyngo-Conjunctival,Human Adenovirus Infection,Infection, Human Adenovirus,Pharyngo Conjunctival Fever
D000260 Adenoviruses, Human Species of the genus MASTADENOVIRUS, causing a wide range of diseases in humans. Infections are mostly asymptomatic, but can be associated with diseases of the respiratory, ocular, and gastrointestinal systems. Serotypes (named with Arabic numbers) have been grouped into species designated Human adenovirus A-G. APC Viruses,APC Virus,Adenovirus, Human,Human Adenovirus,Human Adenoviruses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
August 2012, Journal of virology,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
January 2012, Journal of virology,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
June 2005, Journal of immunology (Baltimore, Md. : 1950),
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
March 1996, Journal of virology,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
October 1996, Virology,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
February 2012, Journal of virology,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
February 2008, Cell,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
January 2012, PloS one,
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
March 1972, Journal of immunology (Baltimore, Md. : 1950),
Ritu R Bradley, and Lori F Maxfield, and Diana M Lynch, and Mark J Iampietro, and Erica N Borducchi, and Dan H Barouch
August 2008, Molecular therapy : the journal of the American Society of Gene Therapy,
Copied contents to your clipboard!